NO20025227L - Tropanderivater nyttige i terapi - Google Patents

Tropanderivater nyttige i terapi

Info

Publication number
NO20025227L
NO20025227L NO20025227A NO20025227A NO20025227L NO 20025227 L NO20025227 L NO 20025227L NO 20025227 A NO20025227 A NO 20025227A NO 20025227 A NO20025227 A NO 20025227A NO 20025227 L NO20025227 L NO 20025227L
Authority
NO
Norway
Prior art keywords
therapy
derivatives useful
tropane derivatives
tropane
useful
Prior art date
Application number
NO20025227A
Other languages
English (en)
Other versions
NO20025227D0 (no
NO327892B1 (no
Inventor
Manoussos Perros
David Anthony Price
Blanda Luzia Christa Stammen
Anthony Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014046A external-priority patent/GB0014046D0/en
Priority claimed from GB0015835A external-priority patent/GB0015835D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20025227L publication Critical patent/NO20025227L/no
Publication of NO20025227D0 publication Critical patent/NO20025227D0/no
Publication of NO327892B1 publication Critical patent/NO327892B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
NO20025227A 2000-05-26 2002-10-31 Tropanderivater nyttige i terapi NO327892B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0014046A GB0014046D0 (en) 2000-05-26 2000-05-26 Compounds useful in therapy
GB0015835A GB0015835D0 (en) 2000-06-27 2000-06-27 Compounds useful in therapy
PCT/IB2001/000806 WO2001090106A2 (en) 2000-05-26 2001-05-09 Tryasolyl tropane derivatives as ccr5 modulators

Publications (3)

Publication Number Publication Date
NO20025227L true NO20025227L (no) 2002-10-31
NO20025227D0 NO20025227D0 (no) 2002-10-31
NO327892B1 NO327892B1 (no) 2009-10-12

Family

ID=26244452

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20025227A NO327892B1 (no) 2000-05-26 2002-10-31 Tropanderivater nyttige i terapi
NO2010007C NO2010007I2 (no) 2000-05-26 2010-04-08 N-(IS)-3-I3-isopropyl-5-metyl-4H-1,2,4-triasol-4-yl)-exo-8-azabicyklo[3.2.1]okt-8-yl]-1-fenylpropyl-4,4-difluorcykloheksankarboksamid
NO2020019C NO2020019I1 (no) 2000-05-26 2020-06-30 Maraviroc eventuelt i form av et farmasøytisk akseptabelt salt

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2010007C NO2010007I2 (no) 2000-05-26 2010-04-08 N-(IS)-3-I3-isopropyl-5-metyl-4H-1,2,4-triasol-4-yl)-exo-8-azabicyklo[3.2.1]okt-8-yl]-1-fenylpropyl-4,4-difluorcykloheksankarboksamid
NO2020019C NO2020019I1 (no) 2000-05-26 2020-06-30 Maraviroc eventuelt i form av et farmasøytisk akseptabelt salt

Country Status (50)

Country Link
EP (3) EP1284974B1 (no)
JP (2) JP3693957B2 (no)
KR (2) KR100548854B1 (no)
CN (2) CN100355753C (no)
AP (1) AP1965A (no)
AR (2) AR028622A1 (no)
AT (2) ATE260914T1 (no)
AU (2) AU2001252482B2 (no)
BG (1) BG65966B1 (no)
BR (1) BRPI0110955B8 (no)
CA (1) CA2408909C (no)
CR (1) CR10145A (no)
CU (1) CU23288B7 (no)
CY (3) CY2008006I1 (no)
CZ (1) CZ299102B6 (no)
DE (3) DE122008000011I1 (no)
DK (2) DK1526134T3 (no)
DZ (1) DZ3464A1 (no)
EA (2) EA007580B1 (no)
EE (1) EE05110B1 (no)
EG (1) EG24137A (no)
ES (3) ES2401812T3 (no)
FR (1) FR08C0007I2 (no)
GE (1) GEP20063799B (no)
HR (1) HRP20020938B1 (no)
HU (1) HU225810B1 (no)
IL (2) IL152531A0 (no)
IS (1) IS2511B (no)
LT (1) LTC1284974I2 (no)
LU (1) LU91417I2 (no)
MA (1) MA26902A1 (no)
ME (1) ME00555A (no)
MX (1) MXPA02011631A (no)
MY (3) MY153023A (no)
NL (1) NL300338I2 (no)
NO (3) NO327892B1 (no)
NZ (1) NZ521477A (no)
OA (1) OA12264A (no)
PA (1) PA8517101A1 (no)
PE (1) PE20011371A1 (no)
PL (1) PL200551B1 (no)
PT (2) PT1526134E (no)
RS (2) RS51436B (no)
SI (2) SI1526134T1 (no)
SK (1) SK286129B6 (no)
TN (1) TNSN01077A1 (no)
TR (1) TR200400541T4 (no)
TW (1) TWI230160B (no)
UY (1) UY26727A1 (no)
WO (1) WO2001090106A2 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286129B6 (sk) * 2000-05-26 2008-04-07 Pfizer Inc. Tropánové deriváty, ich použitie, spôsob a medziprodukt na ich výrobu, kombinácia a farmaceutická kompozícia s ich obsahom
JP2004537531A (ja) * 2001-06-12 2004-12-16 エスケー コーポレイション 新規フェニルアルキルジアミンおよびアミド類似体
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
ES2263960T3 (es) * 2002-04-08 2006-12-16 Pfizer Inc. Derivados de tropano como moduladores de ccr5.
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
GB0208071D0 (en) * 2002-04-08 2002-05-22 Pfizer Ltd Tropane derivatives useful in therapy
MXPA04011577A (es) * 2002-05-23 2005-03-07 Pfizer Metodo para la identificacion de un ligando, por el cual se mide el tiempo de residencia del receptor.
DE60323133D1 (de) * 2002-12-13 2008-10-02 Smithkline Beecham Corp Cyclohexylverbindungen als ccr5-antagonisten
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
DE10336274A1 (de) * 2003-08-07 2005-03-10 Honeywell Specialty Chemicals Verfahren zur Herstellung von geminalen Difluoralkanen
BRPI0413330A (pt) 2003-08-29 2006-10-10 Ranbaxy Lab Ltd inibidores de fosfodiesterase do tipo iv, composição farmacêutica contendo os mesmos e processo para sua preparação
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
PL1682545T3 (pl) * 2003-10-03 2008-04-30 Pfizer Podstawione imidazopirydyną pochodne tropanu o aktywności antagonisty receptora ccr5 do leczenia hiv i stanu zapalnego
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
EP1761542B1 (en) 2004-06-09 2008-01-02 F.Hoffmann-La Roche Ag Octahydropyrrolo[3,4-c]pyrrole derivatives an their use as antiviral agents
CA2586231A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
US20070026441A1 (en) 2005-07-22 2007-02-01 Olson William C Methods for reducing viral load in HIV-1-infected patients
CA2625047A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
AU2007258907A1 (en) * 2006-06-12 2007-12-21 Pfizer Products Inc. CCR5 antagonist for enhancing immune reconstitution and treating opportunistic infection in HIV patients
DK2057125T3 (da) 2006-08-16 2011-05-16 Hoffmann La Roche Ikke-nucleosid revers transkriptase-inhibitorer
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
MX2009005881A (es) 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
CA2673566A1 (en) * 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
WO2008132128A2 (en) * 2007-04-27 2008-11-06 Solvay (Société Anonyme) Synthesis of a pharmaceutically active compound
RU2368613C1 (ru) * 2008-02-19 2009-09-27 Институт молекулярной генетики Российской Академии наук (ИМГ РАН) (Статус Государственного учреждения) Равномерно меченный тритием 4,4-дифтор-n-{(1s)-3-[3-(3-изопропил-5-метил-4н-1,2,4-триазол-4-ил)-8-азабицикло[3.2.1]окт-8-ил]-1-фенилпропил}циклогексан карбодиимид
JP2011513317A (ja) * 2008-02-29 2011-04-28 シェーリング コーポレイション Ｈｉｖ感染を防止するための予防薬としてのｃｃｒ５アンタゴニストおよびｈｉｖの伝播を抑制する方法
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
US8592395B2 (en) * 2009-07-24 2013-11-26 Glaxosmithkline Llc Therapeutic compounds
CN102140104B (zh) * 2010-02-03 2014-11-12 中国科学院上海药物研究所 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
SG184176A1 (en) 2010-04-02 2012-10-30 Phivco 1 Llc Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
CN106977511B (zh) * 2011-12-19 2019-04-12 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CZ306455B6 (cs) 2013-04-26 2017-02-01 Zentiva, K.S. Nový způsob syntézy Maravirocu
CN103497164B (zh) * 2013-09-23 2015-12-23 西安近代化学研究所 一种蒽衍生物及其制备方法
CN104304248B (zh) * 2014-10-23 2016-08-10 西北农林科技大学 3-芳基丙酸酯类化合物作为制备杀螨药物的应用
CN104402883B (zh) * 2014-10-24 2016-04-27 艾琪康医药科技（上海）有限公司 4，4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途
CN104387379B (zh) * 2014-11-26 2017-01-11 扬州氟药科技有限公司 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
CN107879963A (zh) * 2016-09-29 2018-04-06 中国科学院上海药物研究所 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
DE69527839T2 (de) * 1994-04-19 2003-01-02 Neurosearch A/S, Ballerup Tropan-2-aldoximderivate als neurotransmitter "reuptake" inhibitoren
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
EP0920306A2 (en) * 1996-07-12 1999-06-09 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU5604998A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU8576098A (en) * 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
WO1999037619A1 (en) * 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
SK286129B6 (sk) * 2000-05-26 2008-04-07 Pfizer Inc. Tropánové deriváty, ich použitie, spôsob a medziprodukt na ich výrobu, kombinácia a farmaceutická kompozícia s ich obsahom

Also Published As

Publication number Publication date
EP1990341A1 (en) 2008-11-12
CR10145A (es) 2008-08-19
KR20030004417A (ko) 2003-01-14
CN1437599A (zh) 2003-08-20
EP1990341B1 (en) 2013-01-23
CA2408909C (en) 2006-06-27
IS6565A (is) 2002-09-24
NO2010007I1 (no) 2010-04-08
BG65966B1 (bg) 2010-07-30
IS2511B (is) 2009-05-15
CZ20023806A3 (cs) 2004-01-14
HUP0302474A3 (en) 2007-05-29
HK1054927A1 (en) 2003-12-19
IL152531A0 (en) 2003-05-29
CY2008006I2 (el) 2009-11-04
SK286129B6 (sk) 2008-04-07
ME00555B (me) 2011-12-20
JP2003534343A (ja) 2003-11-18
HRP20020938B1 (en) 2011-05-31
LU91417I9 (no) 2019-01-02
AP2002002663A0 (en) 2002-12-31
EE200200656A (et) 2004-06-15
DE60102233T2 (de) 2005-01-27
EP1284974A2 (en) 2003-02-26
JP3693957B2 (ja) 2005-09-14
AU2001252482C1 (en) 2001-12-03
PL200551B1 (pl) 2009-01-30
BRPI0110955B1 (pt) 2016-06-28
TNSN01077A1 (fr) 2005-11-10
PA8517101A1 (es) 2002-10-24
CY2022009I2 (el) 2022-05-27
NZ521477A (en) 2004-07-30
PT1526134E (pt) 2008-10-28
CN1279040C (zh) 2006-10-11
PE20011371A1 (es) 2002-01-18
EA200201141A1 (ru) 2003-04-24
CY2008006I1 (el) 2009-11-04
AR028622A1 (es) 2003-05-14
EE05110B1 (et) 2008-12-15
FR08C0007I2 (fr) 2009-01-15
CU23288B7 (es) 2008-06-30
PT1284974E (pt) 2004-06-30
RS20090438A (en) 2010-05-07
TR200400541T4 (tr) 2004-04-21
SI1526134T1 (sl) 2008-12-31
HK1078573A1 (en) 2006-03-17
CY1108451T1 (el) 2014-04-09
CN100355753C (zh) 2007-12-19
OA12264A (en) 2003-11-10
HU225810B1 (en) 2007-10-29
ES2311126T3 (es) 2009-02-01
MY153023A (en) 2014-12-31
TWI230160B (en) 2005-04-01
EP1526134A2 (en) 2005-04-27
EG24137A (en) 2008-08-06
UY26727A1 (es) 2001-12-28
SK16432002A3 (sk) 2004-01-08
LU91417I2 (fr) 2008-04-22
NL300338I1 (nl) 2008-05-01
BG107140A (bg) 2003-05-30
IL152531A (en) 2010-05-17
HRP20020938A2 (en) 2005-02-28
EP1284974B1 (en) 2004-03-03
DZ3464A1 (no) 2001-11-29
AU5248201A (en) 2001-12-03
LTC1284974I2 (lt) 2020-11-10
MXPA02011631A (es) 2003-03-27
AR060159A2 (es) 2008-05-28
EP1526134A3 (en) 2006-11-29
JP4854970B2 (ja) 2012-01-18
DE60102233D1 (de) 2004-04-08
ES2215129T3 (es) 2004-10-01
EA005382B1 (ru) 2005-02-24
KR20050046743A (ko) 2005-05-18
EP1526134B1 (en) 2008-09-03
MY131019A (en) 2007-07-31
SI1284974T1 (en) 2004-08-31
NO2020019I1 (no) 2020-06-30
WO2001090106A3 (en) 2002-03-28
MA26902A1 (fr) 2004-12-20
BRPI0110955B8 (pt) 2021-05-25
RS51436B (en) 2011-04-30
AP1965A (en) 2009-03-04
DE60135685D1 (de) 2008-10-16
YU82202A (sh) 2005-11-28
NO2010007I2 (no) 2013-09-09
NL300338I2 (nl) 2008-06-02
PL359267A1 (en) 2004-08-23
MY156920A (en) 2016-04-15
FR08C0007I1 (no) 2008-04-25
HK1090836A1 (en) 2007-01-05
ATE407134T1 (de) 2008-09-15
CA2408909A1 (en) 2001-11-29
DE122008000011I1 (de) 2008-06-05
CY2022009I1 (el) 2022-05-27
NO20025227D0 (no) 2002-10-31
HUP0302474A2 (hu) 2003-11-28
CN1680371A (zh) 2005-10-12
BR0110955A (pt) 2003-06-03
LTPA2008004I1 (lt) 2020-07-27
EA200401056A1 (ru) 2005-04-28
ME00555A (en) 2011-12-20
ES2401812T3 (es) 2013-04-24
NO327892B1 (no) 2009-10-12
GEP20063799B (en) 2006-04-25
RS50904B (sr) 2010-08-31
CZ299102B6 (cs) 2008-04-23
WO2001090106A2 (en) 2001-11-29
DK1526134T3 (da) 2008-11-17
KR100548854B1 (ko) 2006-02-02
AU2001252482B2 (en) 2006-01-19
DK1284974T3 (da) 2004-06-07
ATE260914T1 (de) 2004-03-15
EA007580B1 (ru) 2006-12-29
JP2005194283A (ja) 2005-07-21
KR100523501B1 (ko) 2005-10-25

Similar Documents

Publication Publication Date Title
NO20025227L (no) Tropanderivater nyttige i terapi
EE04528B1 (et) Teraapias kasutatavad spirofuropridiinide aralklamiinid
NO20021400D0 (no) Terapeutiske konazolinderivater
EP1296697A4 (en) Therapeutic agents - i
NO20032909L (no) Glukopyranosyloksypyrazolderivater samt medikamentell anvendelse derav
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
DK1278750T3 (da) Imidazopyrimidinderivater og triazolopyrimidinderivater
ID26056A (id) Popok sekali pakai
ATE325807T1 (de) Purinderivate
AP2004003147A0 (en) Tropane derivatives useful in therapy
ID26389A (id) Popok sekali pakai
GB0016787D0 (en) Compounds useful in therapy
DE60103537D1 (de) Purinderivate
DK1280809T3 (da) Antitumorecteinascidinderivater
ATE298332T1 (de) Decahydro-isochinolinderivate
NO20023770L (no) Indol-3-ylderivater
ID25571A (id) Popok sekali pakai
ID24782A (id) Popok sekali pakai
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
ATE241622T1 (de) Thiazolidindion-derivate als antidiabetika
NO20030547L (no) Azabicykliske derivater og deres terapeutiske anvendelse
DK1246791T3 (da) Aminomethyl-phenyl-cyklohexanonderivater
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
DE60015576D1 (de) 4-fluoroalkyl-3-halophenyl nortropane
DZ3364A1 (fr) Agent therapeutique cristallin

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: MARAVIROC EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: 07/00143-22 20071107; FIRST REG. NO/DATE: C(2007)4383-COR 20070918

Spc suppl protection certif: 2010007

Filing date: 20100408

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: MARAVIROC EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: 07/00143-22 20071107; FIRST REG. NO/DATE: C(2007)4383-COR 20070918

Spc suppl protection certif: 2010007

Filing date: 20100408

Extension date: 20220920

SPCS Change of name or address of the owner of a supplementary protection certificate

Owner name: PHIVCO-1 LLC, US

Spc suppl protection certif: 2010007

SPCE Application to extend a supplementary protection certificate (spc)

Free format text: PRODUCT NAME: MARAVIROC EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT; REG. NO/DATE: EU/1/07/418/001-010 20071107

Spc suppl protection certif: 2020019

Filing date: 20200630

MK1K Patent expired
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: MARAVIROC EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT; REG. NO/DATE: EU/1/07/418/001-010 20071107

Spc suppl protection certif: 2020019

Filing date: 20200630

Extension date: 20230320

SPCX Expiry of an spc

Spc suppl protection certif: 2010007

Expiry date: 20220920